Concepedia

The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC

Cole Friedes, Michelle Iocolano, Sang Ho Lee, Lian Duan, Bolin Li, Abigail Doucette, Roger B. Cohen, Charu Aggarwal, Lova Sun, William P. Levin,

Radiotherapy and Oncology · 2023 · 34 citations · 29 references

DOI

Concepts

References

29

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text

, , +15

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text

, , +17

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology · 2022 · 1.3K citations · Full text

, , +16

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki et al. · Journal of Clinical Oncology · 2019 · 578 citations · Full text

, , +14